BUB1 and CDK4/6 Dual Inhibition Increases Radiation Sensitivity in Glioblastoma, Lung Cancer, and Triple-Negative Breast Cancer. (PubMed, Biomedicines) - Sep 27, 2026 - " GBM, LC, and TNBC cell lines were treated with BUB1 inhibitor BAY1816032, CDK4/6 inhibitors ribociclib and abemaciclib, and radiation. Persistent RPA32 Ser33 phosphorylation reflects ATR-dependent resection that requires BLM and EXO1 at later stages, supporting sustained resection and unresolved repair leading to increased cell death. Dual inhibition of BUB1 and CDK4/6 represents a promising therapeutic strategy for enhancing radiosensitivity in GBM, lung cancer, and TNBC, particularly in Rb-intact settings."
Journal • Brain Cancer • Breast Cancer • Glioblastoma • Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BUB1 • HRD • RAD51 • RPA2
|
|
Anthony J Davis; Asya Haider Muratoglu; Benjamin Movsas; Corey Speers; Farzan Siddiqui; Rhea Hede-Sakhardande; Shivani Thoidingjam; Shyam Nyati; Stephen L Brown; Sunita Ghosh; Sushmitha Sriramulu
|